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Supporting information:  
Supplementary Figure 1. Accumulation of GPIbα on leukocyte in stimulated whole 
blood. (A) Gating strategy to identify classical (CD14+CD16-) and non-classical/intermediate 
(CD14+CD16+) monocytes. (B) Median Fluorescence intensity (MFI) of GPIba+ staining on 
Classical monocytes in whole blood stimulated with 100 μM TRAP at 37°C under shear 
determined by flow cytometry, n=3. (C) MFI of GPIba+ staining non-classical/intermediate 
monocytes in whole blood stimulated with 100 μM TRAP at 37°C under shear determined by 
flow cytometry, n=3. (D) MFI of GPIba+ staining on monocytes (all subsets), lymphocytes and 
neutrophils in whole blood stimulated with 100 μM TRAP at 37°C under rolling conditions 
determined by flow cytometry, n=3.  (E)  Percentage of GPIbα+ neutrophils in whole blood 
stimulated with 1µg/ml CRP-XL or 100 μM TRAP at 37°C under shear for 0 and 30 minutes, 
n=3-5. Data are mean ± s.e.m. ** P ≤ 0.01, *** P ≤ 0.001, **** P≤ 0.0001 compared to the 0 
min control (B, C) or to monocytes (D) by analysis of variance (ANOVA) and Dunnett post-
test. 
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Supplementary Figure 2. Accumulation of CD41 on monocytes in stimulated whole 
blood. (A, B) Representative plots of CD41 labelling on classical monocytes (A) or non-
classical/intermediate monocytes (B) in unstimulated or TRAP (100 μM)-stimulated whole 
blood under shear for 30 minutes measured by flow cytometry. (C, D) Percentage of CD41+ 
classical monocytes (C), non-classical/intermediate monocytes (D) in whole blood stimulated 
with 100 μM TRAP at 37°C under shear at 0 and 30 minutes, n=3. Data are mean ± s.e.m. ** 
P ≤ 0.01, *** P ≤ 0.001, **** P≤ 0.0001 compared to the 0 min control (C, D) or to monocytes 
by paired Student’s t-test. 
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Supplementary Figure 3. Surface and intracellular accumulation of GPIba on 
monocytes. Representative images of monocytes labelled with CD14 (blue), GPIba (green) 
for PEV and DAPI in nuclei (red) as determined by confocal microscopy.  
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Supplementary Figure 4. Accumulation overt time of GPIbα on monocyte subsets in 
whole blood under shear and stimulated with different agonists. (A) n=4-7 for ADP, n=4 
for CRP-XL, n=3 for U46619 and n=3 for Rhodocytin. Data are shown as mean ± s.e.m. *,#, 
$, £ P ≤ 0.05, compared to the time point 0 minute control for each agonist * ADP, # CRP-XL, 
$ U46619 and £ Rhodocytin by analysis of variance (ANOVA) and Dunnett post-test. 
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Supplementary Figure 5: Characterisation of PEV. (A) Representative flow cytometry dot-
plots showing the number of events in a platelet gate before and after purification of PEV by 
centrifugation. (B) Contamination of PEV with platelets before vs after purification of PEV by 
centrifugation, n=5-8. (C) Number of PEV produced from 3x108 platelets stimulated with CRP-
XL, quantified by flow cytometry or nanoparticle tracking analysis and enriched in CD41a 
expression using the ExoView R100 (number of PEV captured on a CD41a spot), n=3-10. (D, 
E) Unstimulated washed isolated platelets (D) (3x108/ml) or CRP-XL (1 µg/ml) stimulated (E) 
were incubated for 30 minutes at 37°C. PEV were isolated in supernatants following 
centrifugation for 20 minutes at 2000g and 2 minutes at 13000g. Data were acquired using 
nanoparticle tracking analysis. Data are mean ± SEM. *** P<0.001 by one-way ANOVA and 
Bonferroni post-test (C).  
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Supplementary Figure 6: Measurement of CD41+ PEV. (A) Representative plot of CD41 
intensity on platelets (left histogram) and PEV generated by stimulation of platelets with 1 
μg/ml CRP-XL for 30 minutes analysed by flow cytometry (right histogram). (B) Quantification 
of CD41+ frequency (C) and MFI (D) in platelets and PEV, n=3. Data are mean ± SEM. 
*P<0.05, ** P<0.01 by unpaired t-test.  
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Supplementary Figure 7: Characterisation of PEV. (A) Representative plot of Mitotracker 
and PKH67 labelled PEV generated by stimulation of platelets with 1 μg/ml CRP-XL for 30 
minutes analysed by flow cytometry. (B) Size proportion of CD41a+ and CD9+ PEV using 
ExoView R-100. (C) Normalised total number of PEV captured on a control antibody (IgG), 
exosomal markers CD81 and CD63 and platelet markers CD9 and CD41a using the ExoView 
R-100, n=4. (D) CD81, CD63 and CD9 fluorescence intensities of PEV captured on control 
IgG, CD81, CD63, CD9 and CD41a using ExoView R-100, n=4. Data are mean ± SEM.  
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Supplementary Figure 8. Surface and intracellular accumulation of GPIbα on 
monocytes. (A, B) Staining intensity (MFI) of GPIbα on (A) classical monocytes and (B)  Non-
classical/intermediate monocytes, after incubation with PEV for 30 minutes at 37°C under 
shear, before (surface) and after (Total) permeabilisation, n=3. Surface expression was 
normalised to total GPIba expression. Data are from at least three independent experiments 
using three donors and are shown as mean ± s.e.m.  
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Supplementary Figure 9. P-selectin blockade and expression of integrins on monocytes 
in stimulated whole blood. (A, B) Frequency of GPIba+ classical (A) and non-
classical/intermediate (B) monocytes with blockade of P-selectin (G1 clone, 20 µg/ml) in ADP 
(30 µM), TRAP (100 μM) or CRP-XL (1µg/ml)-stimulated whole blood for 30 minutes under 
shear, n=3.  (C, D) MFI of CD11b (αM) (A) and CD18 (β2) (B) on classical monocytes (green 
bars) and non-classical/intermediates (blue bars) in whole blood stimulated with CRP-XL 
(1µg/ml) for 30 minutes under shear determined by flow cytometry, n=3. Data are mean ± 
s.e.m. ** P ≤ 0.01, *** P ≤ 0.001, **** P≤ 0.0001 compared to the normalised IgG control (A, 
B) by analysis of variance (ANOVA) and Dunnett post-test and using repeated measured two-
way ANOVA and Bonferroni post-test (C, D). 
.  
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Supplementary Figure 10. Accumulation of mouse GPIbα or CD41 on monocytes. (A) 
Gating strategy to identify mouse monocytes by flow cytometry. (B) MFI of GPIba+ monocytes 
in whole blood stimulated with 30 μM ADP at 37°C under shear determined by flow cytometry, 
n=4. (C) Representative histogram of mouse monocytes bound to GPIbα+ (left histogram) or 
CD41+ (right histogram) PEV in murine whole blood stimulated with ADP (30µM) for 30 
minutes under shear stress. (D) Representative histogram of mouse monocytes bound to 
GPIbα+ (left histogram) or CD41+ (right histogram) PEV in control mice without instillation, PBS 
and air pollution particles instillated animals. (E) Representative histograms of GPIbα+ (left 
histogram) or CD41+ (right histogram) isolated murine PEV generated upon platelet 
stimulation with ADP (30µM) for 30minutes measured by flow cytometry (F) Representative 
histogram of human monocytes bearing GPIbα from murine PEV used to inject in the platelet 
depleted IL4R/GPIba-Tg mice for intravital microscopy of the TGFb1-stimulated cremaster 
muscle. Data are from at least three independent experiments using three mice and are shown 
as mean ± s.e.m.  
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Supplementary Figure 11. Monocytes accumulate PEV derived marker CD41 in trauma 
patients. (A) Gating strategy on platelets, monocytes, lymphocytes and neutrophils in the 
Golden Hour patient samples. (B) Representative histogram of CD41 expression on 
monocytes, lymphocytes and neutrophils at 60 minutes after trauma. (C) Number of platelets 
in the circulation of patients after trauma (<60min, 4-12h and 48-72h), n=33. Data are mean ± 
s.e.m. * P ≤ 0.05, ** P ≤ 0.01 by ANOVA and Dunnett post-test to T=<60min.  
 
12 
 
 
 
Supplementary Figure 12. Alternative thrombo-inflammatory mechanism of monocyte 
recruitment mediated by PEV.  Platelet activation results in release of PEV which have 
preferential affinity for monocytes in the circulation. P-selectin- and PS-dependent 
accumulation of PEV on monocytes leads to transfer of platelet-derived molecules such as 
GPIbα. Monocytes utilise PEV-derived GPIbα to adhere to VWF exposed at the EC surface 
triggered by TGF-β1 stimulation. CCL5 transferred on the EC surface by PEV will then allow 
monocyte activation and transmigration. This mode of monocyte recruitment offers an 
alternative pathway for monocytes and to migrate into the atherosclerotic plaque and 
contribute to inflammation. 
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Supplementary Material and Methods 
Blood donors and the Golden Hour study 
We obtained blood samples from healthy adult volunteers after written informed consent and 
with the approval of the University of Birmingham Local Ethical Review Committee (ERN_07-
058). Blood obtained from the Golden Hour study cohort was ethically approved by a national 
research ethics committee (reference 13/WA/0399). In the Golden Hour study, blood was 
collected within an hour of major traumatic injury (ISS>8), 4 to 12 hours after and 48 to 72 
hours after injury. All blood samples were stored at room temperature and used within six 
hours of the venepuncture. 
Leukocyte-PEV aggregate formation in whole blood in response to treatment with 
platelet agonists 
To determine platelet-leukocyte aggregate formation, blood was collected from healthy 
volunteers into a tube containing 10% citrate phosphate dextrose solution (CPDA, Sigma-
Aldrich, Poole, UK).  Blood was incubated at 37°C following treatment with 1µg/ml CRP-XL 
(provided by Prof. Farndale Group, Department of Biochemistry, University of Cambridge) or 
30µM ADP (Sigma) (P2Y1 P2Y12 agonist) or 10 µM U46619 (Cayman Chemical, Michigna, 
USA) (Thromboxane A2 receptor agonist) or 100nM Rodocytin (gift from Johannes Eble, 
University of Munster) (CLEC-2 agonist) or 100 µM TRAP (Alta Bioscience, Birmingham, UK) 
(PAR1 agonist)  for up 2 hours on a roller mixer to apply shear to the samples. For controls, 
blood was either incubated, untreated for 30 or 60 minutes, or fixed immediately after 
phlebotomy.  Following incubation, 300µl of blood was fixed with 300µl of 1% (w/v) 
formaldehyde (Sigma-Aldrich) for 10 minutes followed by two wash steps at 500g for 5 minutes 
in 3ml PBS (Sigma-Aldrich).  Samples were incubated with the following antibodies; 
Phycoerythrin (PE) labelled anti-CD14 (MEM-18) (ImmunoTools), FITC labelled anti-CD16 
(YYF701101) (Alere, Waltham, US) and APC labelled CD42b (HIP1) (BD-Pharmingen, 
Oxford, UK) or relevant isotype controls (Ebioscience, Altrincham, UK). In some experiments, 
monocytes were labelled using: FITC-labelled anti-CD49d (44H6, Abcam), anti-CD11b 
(ICRF44, Ebioscience), anti-CD18 (212701, R/D Systems), or anti-PSGL1 (FLEG, 
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Ebioscience), or PE-labelled anti CD29 (P5D2, R/D Systems) and. Red cells were lysed using 
ACK lysis buffer (Gibco, Life technologies, Paisley, UK) according to manufacturer’s 
instructions. To remove any residual ACK an additional wash step was added using 10ml PBS.  
Samples were suspended in 300μL PBS.  Data were acquired using a Dako Cyan flow 
cytometer.  A total of 2x104 events were collected in the monocyte gate (CD14 positive cells). 
Summit version 4.3 was used to analyse acquired flow cytometry data.  Monocyte population 
was defined by size and granularity, as well as by CD14 and CD16 expression, to ensure 
minimal contamination by other blood cells.  Monocytes fell into two populations, CD14+CD16- 
(Classical monocytes) (~90% population) and CD14+/dimCD16+ (Non- classical/Intermediate 
monocytes) (~10% population) (Supplementary Figure 1A).  GPIbα and CD14 dual positive 
staining indicated Classical monocyte-PEV formation and GPIbα and CD16 dual positive 
indicated Non- classical/Intermediate monocytes-PEV. The neutrophil and lymphocyte 
populations were defined by size and granularity and PEV identified using GPIba.  The zero 
minute time point was used for gating on GPIbα positive events for each of the leukocyte 
subsets. The gates were not changed between samples and leukocyte platelet-aggregates 
were recorded for each time point. To determine the MFI of the platelet/PEV-leukocyte 
aggregates, a gate was set on the platelet/PEV-leukocyte aggregates, which would include 
the equivalent of 95% of the total population of resting platelets expressing GPIba.  This was 
defined as the ‘platelet’ gate.  A gate was set to include the remaining events, with a low GPIbα 
MFI. This was defined as the ‘PEV’ gate. This gating strategy allowed us to quantify the MFI 
for a specific accumulation of PEV on monocytes without including rare platelet-leukocyte 
aggregates.  
In some experiments, 20μg/ml of mouse anti-human P-selectin blocking antibody (G1) or 
unlabelled mouse IgG1 (clone P3.6.2.8.1) (Ebiosience), or 10μg/ml anti-human CD31 blocking 
antibody (clone L133.1, BD Bioscience), or 10μg/ml anti-human ICAM-2 (clone AF244, 
Biotechne), or 20μg/ml anti-human CD18 (clone IB4, Merk Millipore), or 30μg/ml anti-human 
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PS (clone 05-719, Merk Millipore) were added to 300μL of whole blood (collected into 10% v/v 
CPDA from healthy volunteers) before the aggregation assay. 
PEV generation 
Whole blood was collected in 10% CPDA solution with adenine (Sigma-Aldrich) and 
centrifuged at 250 x g for 15 minutes after addition of 10% v/v theophylline solution (60mM 
theophylline 4.8mM D-glucose in phosphate buffered saline without Ca2+/Mg2+; 0.2μm pore-
filtered) (Sigma-Aldrich). Platelet-rich plasma was collected and washed in theophylline-
albumin solution (theophylline solution with0.15% bovine albumin fraction V solution) by 
centrifugation at 800g for 15 minutes. The number of platelets was counted using a Beckman 
Coulter Z2 cell & particle counter according to manufacturer’s instructions. Platelets were 
resuspended in 100μl per 3 x 108 platelets and stained with APC anti-CD42b antibody (HIP1) 
(BioLegend) (20 μl per 100μl containing 3 x 108 platelets) or APC isotype (BioLegend) (5 μl 
per 100μl containing 3 x 108 platelets) for 30 minutes at 4˚C. Platelets were alternatively 
labeled with PKH67 dye using the PKH67 Green Fluorescent Cell Linker Kit (Sigma-Aldrich) 
as manufacturer’s instructions. Briefly, platelet pellets containing 3 x 108 platelets each, were 
resuspended in 750 μl Diluent C. In a fresh tube 15 μl of dye was diluted in 750 μl of Diluent 
C. The dye solution was added to the cell solution and left to incubate at room temperature for 
5 minutes with periodic mixing. An equal volume of 1.5% Bovine Albumin Fraction V solution 
(7.5%, Life Technologies) in diluted theophylline solution was added to the stained cells and 
left to incubate for 1 minute to stop the reaction. Cells were then washed by centrifugation at 
700g for 10 minutes at 20-25 ˚C. The pellet was rewashed twice in 10 ml of the same solution. 
Stained platelet pellets were resuspended in 1ml PBS-Albumin solution (0.15% bovine 
albumin fraction V solution, phosphate buffered saline with Ca2+/Mg2+) (0.2μm pore-filtered) 
and stimulated with 1µg/ml CRP-XL at 37 ˚C for 30 minutes to generate PEV. Samples were 
centrifuged at 2000 x g for 20 minutes to pellet platelets. The supernatants containing PEV 
were transferred in fresh tubes leaving behind ~100 μl in order to prevent contamination with 
the platelet pellet and were further centrifuged at 13 000 x g for 2 minutes to pellet any platelet 
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remnants. The supernatants containing pure PEV were then transferred in fresh tubes leaving 
behind ~100 μl in order to prevent contamination with pellet. Samples were analysed using an 
Accuri C6 Flow Cytometer (BD Bioscience, Oxford, UK). PEV gating was determined by 
running microspheres of <1μm in size. PEV gated on size with this method were on average 
80-90% positive for GPIbα (Figure 3A) and were used in our recruitment assays to bind to 
monocytes.  
Nanoparticle tracking analysis (NTA) to determine the size and number of PEV. 
Total PEV concentration and size distribution in PEV samples were determined using a 
Nanosight LM10 (Malvern Instruments, UK) equipped with NTA software 2.2 as described 
previously.1 Maximum possible detection was achieved by optimizing the concentration of 
PEV to get 108-109/ml, by diluting with filtered phosphate buffered saline (PBS; Sigma).  
Approximately 300μL of the diluted sample was introduced into the Nanosight chamber 
mounted on the light microscope platform, and a laser was illuminated by laser at an angle to 
the optical axis of the microscope. The scattered light illuminates the particles and the video 
images were captured through digital camera attached to the microscope at a rate of 30/s for 
60 seconds. NTA software 2.2 analyses the sample by tracking the movement of individual 
particles to determine the particle size and total particle count. Pre and post-acquisition 
parameters for measuring PEV samples were optimized and maintained constant between 
samples. The camera gain set to 1 and camera shutter set to 250 and the detection threshold 
set at 8. Each video was analysed to give the mean, mode, and median vesicle size and an 
estimate of the concentration of PEV/ml. On average, this method generated 1.6x108 ± 
2.7x107PEV/ml. 
PEV Characterisation by ExoView R-100 
PEV were detected by the ExoView R100 reader (NanoView Biosciences, Boston, MA, USA). 
This technique utilises chip-based antibody capture and Single Particle Interferometric 
Reflectance Imaging Sensor (SP-IRIS) technology to capture and resolve particle size down  
between 50-200 nm. Captured PEV can then be labelled with secondary fluorescent 
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antibodies, thus allowing for identification of different populations of EVs and for identification 
of vesicles <50 nm in diameter. Tetraspanin Plasma chips (NanoView Biosciences, Boston, 
MA, USA) were used for all samples. These silicon chips were arrayed with capture antibodies 
against human CD63, CD81, CD9, CD41a and Mouse IgG. 
PEV were thawed via a 10-minute incubation at 37oC in a water bath. PEV were then 
transferred to 1.5ml Eppendorf(s) and centrifuged at 3000 x g for 20 minutes to pellet any 
remnant cellular material. Supernatants were collected and diluted 1:100 in PBS with 0.05% 
tween (PBST). Chips were carefully placed in the centre of separate wells in a 24 well plate. 
35 μl of diluted sample was applied to each chip. 1ml of distilled, 0.22 filtered water was added 
to the void space between wells to form a humidity chamber; the plate was sealed and allowed 
to incubate for 16 hours at room temperature in the dark. Wells containing chips were washed 
three times in PBST. Following the final wash, a fluorescent antibody cocktail of CD9-Alexa 
488, CD81-Alexa-555 and CD63-Alexa-647 was applied with a final immunostaining ratio of 
1:6000. The plate was incubated for one hour at room temperature in the dark. Wells 
containing chips were then washed with PBST once and washed a further three times with 
PBS.A final wash was performed with distilled, 0.22 filtered water. After each wash the plate 
was shaken at 500 rpm (LSE Digital Microplate Shaker, Corning) for three minutes. The chips 
were then dried and imaged with the ExoView R100 reader using the nScan2 Version 2.76 
acquisition software. Data were analysed using NanoViewer Version 2.82 with fluorescence 
gating based on Mouse IgG capture background. 
Monocyte-PEV aggregate generation 
Some assays required isolated monocyte-PEV aggregates. PBMC were collected from 
EDTA-anticoagulated whole blood using histopaque density gradient centrifugation as 
described previously.2 Monocytes were isolated using CD14+ beads (Miltenyi Biotec, Surrey, 
UK) according to manufacturer’s instructions, to yield isolated monocytes with >95% purity.  
Unlabelled PEV were generated (as described above) and stored at -20˚C.   1x106 monocytes 
were suspended in 0.15% w/v PBSA (control) or PEV (generated from 3x108 platelets), and 
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samples were incubated at 37°C for 30 minutes on a roller mixer to apply shear to the samples. 
Approximately 2-3 x 108 platelets and 1 x 106 monocytes can be found in 1 ml of blood. We 
therefore generated PEV from the number of platelets found in 1 ml of blood to add to the 
number of monocytes found in 1 ml of blood in order to standardise our assays as close to 
physiological conditions as possible. Monocyte-PEV aggregates were either labelled for flow 
cytometry with PE labelled anti-CD14 (MEM-18) (Immuno Tools), FITC labelled anti-CD16 
(YYF701101) (Alere) and APC labelled anti-CD42b (clone HIP1) (BD-Pharmingen) or relevant 
isotype controls (Ebioscience, Altrincham, UK) as described above or used for flow-based 
adhesion assays on VWF and EC (see below). 
Microscopy 
Unstained isolated monocytes (1 x 106) were incubated with purified unstained PEV 
(generated from 3 x 108 platelets) on a roller for 30 minutes at 37°C. The cell suspension was 
then centrifuged at 400g for 6 minutes and the pellet containing monocyte-PEV aggregates 
was resuspended in medium 199 without phenol red (Thermo Fisher Scientific). 1.5 x 
105 monocytes were plated on glass microwell plates (MatTek Corporation, Massassushets, 
US) that had been coated in advance with poly-l-lysine solution (Sigma) for 5 minutes at RT, 
washed with tissue culture grade water and left to dry for 2-3 hours before introducing cells 
and medium. Aternatively, cells were plated in ibiTreat slides (Thistle Scientific). Plated cells 
were incubated at 37°C for 30 minutes in a CO2 incubator. The cells were then fixed in 2 % 
formaldehyde solution (Sigma) for 10 minutes. Following fixation, the surface was blocked with 
BSA (Thermo Fisher Scientific) for 10 minutes.and washed with Dulbeco’s phosphate buffered 
saline (Sigma). Cells were incubated with anti-CD14-Alexa Fluor 647 (clone EPR3653, 1:200, 
abcam), DAPI (5 ng/ml), FCR blocking reagent (1:100, Miltenyi Biotec) and either GPIbα alpha 
/ IgG1 isotype-Alexa Fluor 488 (Clone HIP1, 1:200, Novus Biologicals) for 60-90 minutes at 
4°C and washed in PBS. Plates were saved at 4°C until imaging. Fluorescent images 
produced by an N-STORM microscope (Nikon, Tokyo, Japan) or a Zeiss LSM 780 microscope 
were processed using the ImageJ software. Z-stacks produced by fluorescence microscopy 
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were used to create composite images to show total PEV-derived GPIbα on monocytes. 
PKH67 labelling on monocytes/PEV aggregates were imaged by z-stacking (0.2um step) with 
a confocal microscope (Zeiss LSM780). Z-stacks were used to produce composite images 
showing total PEV signal on the monocytes using FIJI software (maximum projection for 
PKH67 and Dapi, average projection for CD14). 
Flow based adhesion assay on purified VWF 
Capillary tubes of rectangular cross section (0.1 × 1.0 mm, 50 mm long, Camlab, Cambridge, 
UK) were coated with 0.1 mg/mL VWF (HTI, Vermont, USA -HCVWF-0190) overnight at 4°C. 
The capillaries were washed and blocked with PBS containing 2% bovine serum albumin 
(BSA) for 2 hours at room temperature.  Capillaries were then rinsed with 0.15% PBSA (PBS 
containing 0.15% BSA), and connected to a flow system containing reservoirs filled with either 
monocytes ± PEV, or PBSA (wash buffer).  Monocytes ± PEV were i prepared as described 
above and were perfused through the VWF-coated microcapillary at a wall shear rate of 1000s-
1 for 1 minute.  Shear rate was then reduced to 100s-1, for a further 5 minutes. Monocyte ± 
PEV adhesion was monitored at 100s-1.  At least 6 different microscope fields (20 × objective) 
were captured for 10s. Image analysis was performed off-line using ImagePro plus software 
(DataCell Limited, Berkshire, United Kingdom). The numbers of adherent cells were counted 
in each field, averaged and converted to cells per mm2 per 106 cells perfused.  In some 
experiments, GPIbα was blocked using an anti-GPIbα antibody (clone 6B4, courtesy of Prof. 
H. Deckmyn, University of KU Leuven Kulak) at 20 µg/ml during incubation of monocytes with 
PEV for 30 minutes under shear.  
Flow based adhesion assay on EC monolayers 
Human dermal blood endothelial cells (HDBEC) (Promocell, Heidelberg, Germany) were 
passaged four times and frozen. HDBEC were defrosted in 25cm2 flasks and seeded into Ibidi 
6 channels µ-slides (Ibidi, Martinsried, Germany). After 24 hours, HDBEC were stimulated 
with TGF-beta (10 ng/ml, R/D Systems) for 24 hours in order to up-regulate VWF at the cell 
surface. Monocyte ± PEV were prepared as described above and were perfused on HDBEC 
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monolayers in the µ-slides for 4 minutes at a wall shear stress of 0.1Pa. Monocyte ± PEV 
adhesion and migration was assessed using a phase-contrast videomicroscope as described 
previously.3 Manipulations and microscopy were carried out at 37°C and at least 6 different 
microscope fields (20 × objective) were analysed. Recordings were digitized and analysed 
offline using Image-Pro Plus software (DataCell, Finchampstead, U.K.). The numbers of 
adherent cells were counted in each field, averaged and converted to cells per mm2 and 
multiplied by the known surface area of the EC monolayer to calculate the total number 
adherent. This number was divided by the known total number of monocytes perfused to 
obtain the percentage of the monocytes that had adhered. In some experiments, GPIbα was 
blocked using an anti-GPIbα antibody at 20 µg/ml (clone 6B4) during incubation of monocytes 
with PEV for 30 minutes under shear.  
FITC-Phalloidin staining of monocyte bound to platelets 
For the FITC-phalloidin stainings, blood was collected from healthy volunteers by 
venepuncture of the ante-cubital vein, into vacutainers containing dipotassium 
ethylenediamine tetra acetic acid ( K2 EDTA) (Becton & Dickinson UK. Ltd, Oxford).  FITC-
phalloidin (Molecular Probes, 300U) stock (5.6µM) was prepared by dissolving 0.1mg (300 
units) in 1.5ml of methanol and stored at -20ºC until used. A Cell Permeabilisation Kit 
(Invitrogen, Molecular Probes) was used according to the manufacturer's instructions.  Cells 
then stain with FITC-phalloidin and were visualised in an Olympus microscope (Olympus 
Optical Co. LTD, Japan). The cells were viewed on the x100 oil immersion objective. 
Animal experiments 
All experiments were performed in accordance with Home Office Guidelines and with approval 
of a local ethics committee. In each experiment C57BL/6 IL4R/GPIbα−Τg or wild-type (WT) 
animals with the same background were allocated at random to different experimental groups. 
Importantly, mice from the same litter were randomly distributed amongst the experimental 
groups and where possible, were equally distributed amongst experimental groups.  
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Leukocyte-PEV aggregate formation in murine whole blood in response to treatment 
with platelet ADP 
Platelet-leukocyte aggregate formation was assayed in blood collected from WT mice 
into a tube containing 10% citrate phosphate dextrose solution (CPDA, Sigma-Aldrich, Poole, 
UK) following cardiac puncture. Blood was incubated at 37°C on a roller mixer to apply shear 
to the samples, following treatment with 30µM ADP (Sigma) for up 30 minutes and samples 
for analysis were retrieved at 5, 15 and 30 minutes. For control samples, blood was either 
fixed shortly after collection or incubated on a roller mixer for 30 minutes without ADP.  
Samples for analysis were fixed with 1% (w/v) formaldehyde (Sigma-Aldrich) for 10 minutes, 
washed twice (500g for 5 minutes). Red cells were lysed using ACK lysis buffer (Gibco, Life 
technologies, Paisley, UK) according to manufacturer’s instructions. Residual ACK was 
removed by washing in a large volume of PBS. Samples were incubated with the following 
antibodies for 30 minutes at 4°C, Phycoerythrin (PE) labelled anti-CD115 (clone AFS98), APC 
labelled anti-F4/80 (clone BM8), PerCp Cy5.5 labelled anti-CD3 (clone 145-2C11) (all from 
Ebioscience, Altrincham, UK), FITC labelled anti-GPIbα (XiaG5, Emfret, UK) and anti-CD41 
(MWReg30, BD Pharmingen) or relevant isotype controls (Emfret, UK). Samples were 
suspended in 300μL PBS.  Data were acquired using a Dako Cyan flow cytometer. Flowjo 
(Treestar) was used to analyse acquired flow cytometry data. Monocyte population was 
defined by size and granularity, T-cells where gated out using CD3 and monocytes gated 
using F4/80 and CD115 (Supplementary Figure 9A). Percentage of GPIbα positive monocytes 
was determined using gating on the isotype control for each animal.  
Intratracheal instillations of air pollution particles 
Male 9–12-week-old wild type (WT) C57BL/6 mice, with an average body weight of 25 g were 
obtained from Harlan UK Limited, Oxford, UK and maintained in the Biomedical Services Unit, 
Birmingham University, UK. Intratracheal (IT) instillations were performed as previously 
described.4 Briefly, mice were anaesthetised using intraperitoneal injections of metetomidine 
(60 mg/kg) and ketamine (10 mg/kg) and a fine polyethylene catheter (external diameter 0.61 
mm and internal diameter 0.28 mm) passed into the trachea via the mouth under direct 
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visualisation of the vocal cords. 400 µg of air pollution particles (Urban particulate matter, 
Standard Reference Material 2786; National Institute for Standards and Technology, 
Gaithersburg, MD 20899, USA) in 50 µL sterile PBS or PBS alone were instilled. Mice were 
given 0.1 mL atipamezole to reverse the metetomidine and hydrated with two 0.5 mL saline 
subcutaneous injections, one immediately post IT and another 6 h later. 
To determine monocyte-platelet aggregate formation, blood was collected from treated 
mice 48 hours after instillation, by cardiac puncture into a tube containing 10% citrate 
phosphate dextrose solution (CPDA, Sigma-Aldrich, Poole, UK). Blood was processed and 
assayed for flow cytometry as described above. 
Intravital imaging of the cremaster muscle and the carotid artery 
 
Mouse PEV were generated by stimulating isolated platelets with 10 µg/ml CRP-XL 5, 
6 and purified as described in the section on PEV generation from human platelets. Human 
monocytes were isolated as described above, and incubated with mouse PEV from 30 minutes 
under shear. CFSE (ThermoFisher) was added at 10µM during the last 10 minutes of 
incubation to label monocytes. Monocyte/PEV were washed twice in PBS and resuspended 
in PBS-BSA for adoptive transfer. When desired, GPIbα function was blocked using an anti-
GPIbα antibody at 50 µg/ml (Xia.B2, Emfret) during incubation of monocytes with PEV for 30 
minutes under shear. 
IL4R/GPIbα−Τg mice were genotyped by measuring expression of the IL4R (anti-
human CD124-Phycoerythrin, BD Biosciences) using flow cytometry. For intravital 
microscopy, anti-human IL4 receptor antibody (2.5 μg/g, R/D Systems) was administrated to 
IL4R/GPIbα−Τg mice intravenously 24 hours before microscopy.7 The resultant 
thrombocytopenic IL4R/GPIbα−Τg animals were injected intrascrotally with 80 µg/kg TGF-β1. 
After 4 hours, anesthetized animals (100 mg/kg ketamine hydrochloride, Zoetis UK, UK; 10 
mg/kg xylazine hydrochloride, Chanelle Animal Health, UK; intraperitoneally) underwent 
tracheotomy and carotid cannulation to facilitate infusion of labelled cells. The cremaster 
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muscle was then exposed and CFSE labelled monocytes/PEV (1.5million) ± anti-GPIbα 
antibody were injected via the carotid artery. Post-capillary venules with a diameter of 20–40 
μm were selected for study and at least three vessels in each mouse were video-recorded for 
monocyte/PEV adhesion. Data are expressed as adhesive interactions of monocytes per mm 
of vessel segment/minute. 
ApoE-/- mice were genotyped using the ISOLATE Genomic kit according to 
manufacturer’s instructions.  At 10 weeks, ApoE-/- mice were placed on a Western diet (21.4% 
cocoa butter [w/w] and 0.2% cholesterol [w/w]; Special Diet Services, UK) for 6 weeks. 
Anesthetized animals (100 mg/kg ketamine hydrochloride, Zoetis UK, UK; 10 mg/kg xylazine 
hydrochloride, Chanelle Animal Health, UK; intraperitoneally) underwent tracheotomy and left 
carotid cannulation to facilitate infusion of labelled cells. The right carotid was then exposed 
and CFSE labelled monocytes/PEV (1.5million) ± anti-GPIbα antibody injected via the left 
carotid artery. Recruitment to the carotid using a 10x objective and recorded for 4 minutes 
near the carotid bifurcation. Data are expressed as adhesive interactions of monocytes per 
mm of vessel segment per minute. 
Exposed carotid and cremaster muscle were visualized using an inverted intravital 
microscope (Olympus IX-81, Olympus, Essex, UK). Data were stored digitally and analysed 
off-line (Slidebook, Intelligent Imaging Innovations, Denver, CO, USA). 
Flow cytometry of Golden Hour samples 
25 µl aliquots of citrated whole blood were mixed with 74 µl of Hepes buffered saline 
(0.145 mMol/L NaCL, 5 mMol/L KCL, 1mMol/L MgSO4) and stained with 1 µg/ml FITC-labelled 
mouse anti-human CD41 (clone 5B12; Dako, Cambridgeshire, UK) or its concentration-
matched isotype control for 10 minutes at room temperature (RT). Post incubation, samples 
were fixed for 10 minutes at RT in 2% formaldehyde, after which red blood cells were lysed. 
For flow cytometric analysis, which was performed on an Accuri C6 flow cytometer (BD 
Biosciences, Oxford, UK), monocytes were gated according to their forward and sideward 
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scatter properties and CD41 expression measured as the percentage of CD41+ monocytes 
and median fluorescent intensity. Data was analysed using CFlow software (BD Biosciences).   
Statistical analysis 
Statistical analysis was carried out using GraphPad Prism software (GraphPad 
Software Inc., La Jolla, CA, USA).  Normality of data was checked using the 
Kolmogorov–Smirnov test.  Differences between individual treatments or groups were 
analysed by paired or unpaired t-test as appropriate. One or two-way analysis of 
variance (ANOVA)  was used for multiple group comparison followed by a post hoc 
analysis where appropriate, using Bonferroni test for comparisons between groups or 
Dunnet tests for comparisons to a control group.  P values  ≤0.05 were considered 
significant. 
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